Philip B. Rawlins

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Adriana E. Tron, Matthew A. Belmonte, Ammar Adam et al. · Nature Communications · 2018 · 486 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Jessie Hao-Ru Hsu, Timothy Rasmusson, James Robinson et al. · Cell chemical biology · 2019 · 197 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +5

Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain

Gizem Akçay, Matthew A. Belmonte, Brian Aquila et al. · Nature Chemical Biology · 2016 · 194 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6

William McCoull, Tony Cheung, Erica Anderson et al. · ACS Chemical Biology · 2018 · 139 citations · Full text

Medicine, Medicinal Chemistry, Oncology +14

Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors

William McCoull, Roman Abrams, Erica Anderson et al. · Journal of Medicinal Chemistry · 2017 · 78 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17